drugset
drugset / Trial / NCT06113471

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NCT06113471 ↗

Phase 3 Active not recruiting 450 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Timeline

Start
2023-11-27
Primary completion
2026-03-17
Completion
2027-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — Oral

Indications

vitiligo